<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369600">
  <stage>Registered</stage>
  <submitdate>23/11/2015</submitdate>
  <approvaldate>25/11/2015</approvaldate>
  <actrnumber>ACTRN12615001285549</actrnumber>
  <trial_identification>
    <studytitle>An evaluative study to assess the safety of Nanocelle (Trademark) Atorvastatin Formulation Administered Oro-buccally (by mouth spray)  in Healthy Adult Volunteers. </studytitle>
    <scientifictitle>A Phase 0, Multi-dose, Open-label,  Clinical Trial To Investigate The Safety of a Micro-dose of a Nanocelle (Trademark) Atorvastatin Formulation Administered Oro-buccally in Healthy Adult Volunteers</scientifictitle>
    <utrn>U1111-1176-3474</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition> Hyperlipidaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The clinical study will investigate the tolerability and safety of Nanocelle Atorvastatin. The patient will be instructed to initially administer oro-buccally 0.01 mg of atorvastatin per spray once a day. Administration of additional sprays will be a maximum of 1 spray over 24 hours for a total of 7 days..

Schedule Dose: Day 1: Administer 1 spray oro-buccally 5 minutes prior to P.K collection, a maximum dose of 0.01mg/day. 
Schedule Dose: Days 27: Administer 1  spray once a day [maximum day 17 dose 0.01 mg / day]


Duration: 7 Days
Methods and tools used to monitor side effects and toxicity 1) Participant diary</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate to safety and tolerability of Micellised atorvastatin. Tests will be performed include: liver function test, full blood evaluation, blood lipids, urea and electrolytes, blood pressure, ECG, pharmacokinetic data, SF-12 general health questionnaire, and participant diary to capture adverse events.</outcome>
      <timepoint>Safety and tolerability will be assessed during an acute phase (day 1, 0-24 hours) and a delayed phase (Day 2-Day 7). 
Blood test(Liver function test, full blood evaluation, blood lipids, urea and electrolytes) will be performed at baseline, day 2 and day 7.
Pharmacokinetic blood samples will be taken at baseline, and after dosing (30 minutes, 1 hour, 2 hour, 4 hour and Day 7).  
ECGs are performed at screening, Day 1 and Day 7
Blood pressure test will be performed at baseline, and after dosing (30 minutes, 1 hour, 2 hour, 4 hour and Day 7).  
SF-12 general health questionnaire will be performed daily from Day 1 to Day 7.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Participant adherence to the intervention</outcome>
      <timepoint>Participant is given a medication diary to capture daily dosing for 7 days.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Participants greater than or equal 18 years of age up to and including 80 years ago at time of entry on study 2) Cognitive ability to understand informed consent process and to give informed consent to the experimental treatment 3) Participants agree to undergo venepuncture on multiple occasions 4) Participants agree to adhere to the study protocol 5) Hyperlipidaemic 6) Normal ECG reading QTcF &lt; 450 msec 7) No history of statins reaction</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1) Any clinically relevant abnormal findings which, in the opinion of the investigators / clinicians, may put the participant at risk of adverse events because of participation in the clinical trial including: physical examination, clinical chemistry, haematology, urinalysis, vital signs 2) Previous history of rhabdomyolysis 3) Alcohol abuse 4) The use of any illicit drugs 5) Pregnancy or nursing an infant 6) Any psychiatric disorders by history or examination that would prevent completion of the study or result in possible adverse events for the participant 7) Elevated liver enzymes 2x normal limits</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>All data will be summarized descriptively using n, mean, median, standard deviation and 95% confidence intervals for continuous data, and frequency and percent for categorical data. All tests will be conducted two-sided and p values of less than 0.05 will be considered statistically significant. Data will be analysed on an intent-to-treat basis using STATA MP v13 for Mac. All available data used will be treated as for intentiontotreat analyses. All analyses will be conducted with software from STATA for windows version 13.0 [College Station, Texas] and SPSS for windows, version 21 (SPSS Inc, Chicago).</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 0</phase>
    <anticipatedstartdate>30/11/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>14/12/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medlab Pty Ltd</primarysponsorname>
    <primarysponsoraddress>66 McCauley St, Alexandria NSW 2015</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medlab Pty Ltd</fundingname>
      <fundingaddress>66 McCauley St, Alexandria NSW 2015</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical trial aims to explore the safety and tolerability of Atorvastatin Oro-buccal Spray Micelle. 
Who is it for? All participants who are aged 18 years or over with no allergic reactions to statins
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Institute of Integrative Medicine</ethicname>
      <ethicaddress>21 Burwood Rd, Hawthorn VIC 3122</ethicaddress>
      <ethicapprovaldate>15/09/2015</ethicapprovaldate>
      <hrec>0028E_2015</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Pty Ltd
66 McCauley St.
Alexandria, NSW 2015</address>
      <phone>+61 (02) 8094 1939</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Tony Nguyen</name>
      <address>Medlab Pty Ltd
66 McCauley St.
Alexandria, NSW 2015</address>
      <phone>+61 (02) 8188 0311</phone>
      <fax />
      <email>tony_nguyen@medlab.co</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Pty Ltd
66 McCauley St.
Alexandria, NSW 2015</address>
      <phone>+61 (02) 8094 1939</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Tony Nguyen</name>
      <address>Medlab Pty Ltd
66 McCauley St.
Alexandria, NSW 2015</address>
      <phone>+61 (02) 8188 0311</phone>
      <fax />
      <email>tony_nguyen@medlab.co</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>